Paris, October 29, 2021 – Laboratoire X.O has entered into a transaction with Astellas Pharma Inc. for the rights to nicardipine (3 brands) in 4 European countries. This will strengthen our portfolio of 24 brands and our European footprint.
Since its creation in 2015, Laboratoire X.O has completed 12 M&A transactions and confirmed its position as a reliable partner for Big Pharma in the event of a portfolio sale.
The transaction includes product registrations, intellectual property, certain contracts and inventory. The transaction does not include the transfer of manufacturing facilities or employees.
About Astellas Pharma Inc.
Astellas Pharma Inc. is a pharmaceutical company with operations in more than 70 countries worldwide.
It promotes an area of focus approach, which aims to identify opportunities for the continuous creation of new medicines to treat diseases with unmet medical needs, focusing on biology and modality.
In addition, Astellas is moving beyond its core business of medicines to create Rx+® healthcare solutions that combine its expertise and knowledge with cutting-edge technology in various fields from external partners.
Through these efforts, Astellas is at the forefront of change in healthcare to turn innovative science into value for patients.
For more information, please visit the website at: https://www.astellas.com/en
About Laboratoire X.O
Founded in 2015, Laboratoire X.O (“X.O”) is a French pharmaceutical company that operates a range of mostly non-generic prescription medicines in France and internationally. X.O focuses on “princeps ” drugs for the treatment of chronic diseases, with proven efficacy and safety and strong brand awareness.
Since its creation, X.O has made numerous acquisitions to broaden its product portfolio and its range of expertise. Today, X.O brings together teams with expertise in quality management, regulatory issues, logistics/distribution, marketing and sales. X.O operates as an agile platform, outsourcing all production to leading subcontractors in Europe.
X.O is committed to being as close as possible to the needs of healthcare professionals and patients for its medicines, medical devices and cosmetics.
X.O’s growth is fuelled by the success of its brands, its international expansion and its external acquisition strategy.
Antoine WISNIEWSKI (France)
Download the press release in French.